Compositions of quaternary ammonium compounds containing bioavailability enhancers
AssigneeSupernus Pharmaceuticals, Inc.
InventorArgaw Kidane
Life of this patent
Estimating the term…
Abstract
An oral pharmaceutical dosage form with enhanced gastrointestinal permeability, comprising a therapeutic quaternary ammonium compound together with an organic acid.
Claims30
A solid oral pharmaceutical dosage form with enhanced gastrointestinal permeability, comprising two separate solid components:
- (a) a therapeutically effective amount of a quarternary ammonium salt compound, and (b) a permeability enhancing amount of a granulated organic acid.
An oral pharmaceutical dosage form with enhanced gastrointestinal permeability comprising a multilayered granule comprising a core consisting essentially of a granule of organic acid, and at least one layer comprising a therapeutically effective amount of a quaternary ammonium salt compound surrounding said core.
An oral pharmaceutical dosage form with enhanced gastrointestinal permeability comprising a multilayered granule comprising a core comprising a therapeutically effective amount of a quaternary ammonium salt compound, wherein the core is coated by at least one layer consisting essentially of a permeability enhancing amount of a granulated organic acid.
An oral pharmaceutical dosage form with enhanced gastrointestinal permeability comprising, a permeability enhancer and a quaternary ammonium salt, wherein the permeability enhancer is contained in coated granules and the quaternary ammonium salt is contained in pellets that are separate from the coated granules.
An oral pharmaceutical dosage form with enhanced gastrointestinal permeability comprising from 10 mg to 80 mg of trospium chloride;
- a permeability enhancing amount of a granulated short chain organic acid, and at least one electronegatively charged polymer.
Dependencies are inferred from the claim text.